Results 181 to 190 of about 216,339 (397)

Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens. [PDF]

, 2020
BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy.
Cabral, Howard, Jones, Eric, Ko, Naomi, Leproux, Anais, Mehta, Rita S, O'Sullivan, Thomas, Pera, Vivian, Peterson, Hannah M, Roblyer, Darren, Tabassum, Syeda, Tank, Anup, Tromberg, Bruce J   +11 more
core  

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

Bevacizumab in the therapy for refractory metastatic colorectal cancer

Biologics: Targets & Therapy, 2008
Mary F MulcahyNorthwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USAAbstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States.
Mary F Mulcahy
doaj  

Bevacizumab in combination chemotherapy for colorectal and other cancers [PDF]

, 2005
Susannah E. Motl
openalex   +1 more source

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

New England Journal of Medicine, 2004
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar   +14 more
semanticscholar   +1 more source

DNA Immunotherapy (INO‐3107) Results in Long‐Term Surgery Reduction in RRP

The Laryngoscope, EarlyView.
In a retrospective, observational extension study (RRP‐002) evaluating long‐term safety and clinical effect, DNA immunotherapy INO‐3107 was well tolerated and provided continued clinical effect against HPV‐6 and 11 recurrent respiratory papillomatosis (RRP) that resulted in further reduction of the surgical burden observed in Year 1. The mean number of
Milan R. Amin, Peter C. Belafsky, Simon R. Best, Aaron D. Friedman, Adam M. Klein, David G. Lott, Ted Mau, Randal C. Paniello, Seth M. Pransky, Nabil F. Saba, Christopher Welsh, Stefani A. Slog, Elisabeth Gillespie, Michael Dallas, Matthew P. Morrow, Jeffrey M. Skolnik   +15 more
wiley   +1 more source

Bevacizumab: Improved survival at what cost? [PDF]

, 2005
Jill Kolesar
openalex   +1 more source

Vascularized Tumor‐on‐a‐Chip Model as a Platform for Studying Tumor‐Microenvironment‐Drug Interaction

Macromolecular Bioscience, EarlyView.
Vascularized tumor‐on‐a‐chip platforms replicate human tumor microenvironments by integrating perfusable vessels and stromal elements in microfluidic systems. These models enable dynamic assessment of drug delivery and therapeutic response under physiologically relevant flow, offering enhanced predictive value for cancer treatment.
Hyelim Kim, Seung‐Woo Cho, Hong Nam Kim   +2 more
wiley   +1 more source

Bevacizumab therapy for POEMS syndrome [PDF]

, 2005
Ashraf Badros, Neil Porter, Ann B. Zimrin   +2 more
openalex   +1 more source

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

New England Journal of Medicine, 2006
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David H. Johnson   +7 more
semanticscholar   +1 more source